The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome

Ki, Bong; Jung, Seung Mun; Choi, Chang Hwan; Song, In-Do; Lee, Hyun Woong; Kim, Hyung Joon; Hyuk, Jae; Chang, Sae Kyung; Kim, Ki-Jeong; Chung, Won-Seok; Seo, Jae-Gu

doi:10.1097/mcg.0b013e31823712b1

Cited by 185 publications

(105 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…have evaluated a probiotic mixture containing Lactobacillus and Bifidobacterium and S. thermophilus for 8 weeks and found an overall response rate of 48% versus 12% with placebo; though, it had no significant effect on individual symptoms. [21] The study by Williams et al . on a combination of Lactobacillus and Bifidobacterium species also found greater improvement in IBS symptom severity and also in QOL compared with placebo over the 8-week intervention period.…”

Section: Discussionmentioning

confidence: 99%

The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial

Shavakhi¹,

Minakari²,

Farzamnia³

et al. 2014

Adv Biomed Res

View full text Add to dashboard Cite

Background:Evidence has shown beneficial effects of probiotics in the treatment of irritable bowel syndrome (IBS); however, there is still a lack of data in this regard. We evaluated the efficacy of a multi-strain probiotic compound on IBS symptoms and quality-of-life (QOL).Materials and Methods:Adult IBS patients (n = 132) were randomized to receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles or similar placebo, twice daily after a meal for 14 consecutive days. Improvement of IBS symptoms was assessed in categories of abdominal pain and distension and improvement of bowel habit. Improvement in patients QOL was assessed by the IBS-QOL instrument. Patients were evaluated for symptoms and QOL at baseline and then 1 month after completion of the treatment.Results:After treatment, there was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (P<0.001), but there was no difference between the two groups in this regard (P>0.05). Improvement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910). There was no significant difference between the two groups in QOL after the treatment (P >0.05).Conclusions:We found no beneficial effects over placebo for a 2-week treatment with the above mentioned multi-strain probiotic compound in the treatment of IBS. Further, trials are yet required before a clear conclusion in this regards.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial

Shavakhi¹,

Minakari²,

Farzamnia³

et al. 2014

Adv Biomed Res

View full text Add to dashboard Cite

show abstract

“…The clinical score is considered to reflect the state of gastrointestinal diseases and is used as a reliable assessment tool for IBD patients [18, 31]. DSS-induced colitis in mice presents a variety of clinical symptoms such as diarrhea, bloody stool, or behavioral changes [30].…”

Section: Discussionmentioning

confidence: 99%

“…Duolac7S (DUO) is a probiotic mixture containing seven LAB species including Bifidobacterium , Lactobacillus , and Streptococcus . They are easily available, do not require a prescription, and are extensively used to relieve abdominal symptoms [17] by restoring the ecological balance in intestinal microflora [18]. However, in IBD the effect of DUO and its combination with LJ has not been investigated.…”

Section: Introductionmentioning

confidence: 99%

Protective Effect ofLaminaria japonicawith Probiotics on Murine Colitis

Bae

et al. 2014

Mediators of Inflammation

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronically relapsing inflammatory disorder of the gastrointestinal tract. Most IBD treatments are unsatisfactory; therefore, various dietary supplements have emerged as promising interventions. Laminaria japonica (LJ) is an edible seaweed used to regulate digestive symptoms. Probiotics have been reported to improve digestive problems and their simultaneous administration with seaweeds has been shown to produce synergistic therapeutic effects. Here, we investigated the effect of LJ combination with probiotics on dextran sodium sulfate-induced colitis model in mice. Aqueous LJ extracts (LJE) at doses from 100 to 300 mg/kg and probiotics at a dose of 300 mg/kg were orally administered for 7 days. Body weight, colon length, histological score, macroscopic damage, and the levels of cytokines IFN-γ, IL-1β, IL-6, IL-10, IL-12 (P40), IL-12 (P70), IL-17, and TNF-α were assessed. LJE alone caused a significant improvement of colitis signs such as colon length, histological score, and IL-1β and IL-6 production. LJE and probiotics demonstrated a synergistic effect by the histological score and levels of IL-1β, IL-6, and IL-12 (P40) but not IFN-γ, IL-10, and IL-12 (P70). In conclusion, LJE was effective in inducing protection against colitis in mice and acted synergistically with probiotics.

show abstract

“…However, the clinical effect of probiotics on IBS is still controversial 11. Indeed, 34 out of 42 trials examining the efficacy of LAB in patients with IBS reported beneficial effects in at least one of the endpoints or symptoms examined,12 or an association with the stabilization of the intestinal microbiota 13. The results of other studies are difficult to compare because of the differences in study design and probiotic dose and strain 27.…”

Section: Discussionmentioning

confidence: 99%

“…Accordingly, probiotics are among the pharmacological agents approved for the treatment of IBS, although their clinical efficacy on IBS is still controversial 11. Indeed, 34 out of 42 trials examining lactic acid bacteria (LAB) effectiveness in patients with IBS showed beneficial effects in at least one of the endpoints or symptoms examined12 or an association with the stabilization of intestinal microbiota 13. In contrast, two other studies with LAB did not report any benefit 1415.…”

Section: Introductionmentioning

confidence: 99%

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3

et al. 2014

View full text Add to dashboard Cite

This study was undertaken to evaluate the influence of treatment with rifaximin followed by the probiotic VSL#3 versus no treatment on the progression of chronic prostatitis toward chronic microbial prostate-vesiculitis (PV) or prostate-vesiculo-epididymitis (PVE). A total of 106 selected infertile male patients with bacteriologically cured chronic bacterial prostatitis (CBP) and irritable bowel syndrome (IBS) were randomly prescribed rifaximin (200 mg, 2 tablets bid, for 7 days monthly for 12 months) and probiotic containing multiple strains VSL#3 (450 × 109 CFU per day) or no treatment. Ninety-five of them (89.6%) complied with the therapeutic plan and were included in this study. Group A = “6Tx/6-”: treatment for the initial 6 and no treatment for the following 6 months (n = 26); Group B = “12Tx”: 12 months of treatment (n = 22); Group C = “6-/6Tx”: no treatment for the initial 6 months and treatment in the last 6 months (n = 23); Group D = “12-”: no treatment (n = 24). The patients of Groups A = “6Tx/6-” and B = “12Tx” had the highest frequency of chronic prostatitis (88.5% and 86.4%, respectively). In contrast, group “12-”: patients had the lowest frequency of prostatitis (33.4%). The progression of prostatitis into PV in groups “6Tx/6-” (15.5%) and “6-/6Tx” (13.6%) was lower than that found in the patients of group “12-” (45.8%). Finally, no patient of groups “6Tx/6-” and “6-/6Tx” had PVE, whereas it was diagnosed in 20.8% of group “12-” patients. Long-term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections in infertile patients with bacteriologically cured CBP plus IBS.

show abstract

The Effect of a Multispecies Probiotic Mixture on the Symptoms and Fecal Microbiota in Diarrhea-dominant Irritable Bowel Syndrome

Cited by 185 publications

References 37 publications

The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial

The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial

Protective Effect ofLaminaria japonicawith Probiotics on Murine Colitis

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3

Contact Info

Product

Resources

About